These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4276573)

  • 1. Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.
    Johnson AM; Vigouret JM; Loew DM
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R40. PubMed ID: 4276573
    [No Abstract]   [Full Text] [Related]  

  • 2. Turning behaviour elicited by apomorphine, (+)-amphetamine and three ergot derivatives in rats treated with a unilateral injection of ethanolamine-O-sulphate in the substantia nigra [proceedings].
    Jaton AL; Loew DM; Vigouret JM
    Br J Pharmacol; 1977 Mar; 59(3):464P-465P. PubMed ID: 843708
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
    Cashin CH; Sutton S
    Br J Pharmacol; 1973 Mar; 47(3):658P-659P. PubMed ID: 4738385
    [No Abstract]   [Full Text] [Related]  

  • 4. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD; Creese I
    Adv Neurol; 1975; 9():81-92. PubMed ID: 1170717
    [No Abstract]   [Full Text] [Related]  

  • 5. Ergocornine and 2-Br-alpha-ergocryptine. Evidence for prolonged dopamine receptor stimulation.
    Fuxe K; Corrodi H; Hökfelt T; Lidbrink P; Ungerstedt U
    Med Biol; 1974 Apr; 52(2):121-32. PubMed ID: 4837435
    [No Abstract]   [Full Text] [Related]  

  • 6. Action of m-tyrosine in experimental models: evidence for possible antiparkinsonian activity.
    Ungerstedt U; Fuxe K; Goldstein M; Battista A; Ogawa M; Anagnoste B
    Eur J Pharmacol; 1973 Feb; 21(2):230-7. PubMed ID: 4633120
    [No Abstract]   [Full Text] [Related]  

  • 7. Proceedings: Behavioral effects of direct and indirect acting dopaminergic agonists.
    Moore KE
    Psychopharmacol Bull; 1974 Jul; 10(3):41-2. PubMed ID: 4419323
    [No Abstract]   [Full Text] [Related]  

  • 8. Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors.
    Papeschi R; Randrup A
    Pharmakopsychiatr Neuropsychopharmakol; 1973 May; 6(3):137-57. PubMed ID: 4800160
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine supersensitivity in the hypothalamus?
    Reid JL
    Adv Neurol; 1975; 9():73-80. PubMed ID: 167569
    [No Abstract]   [Full Text] [Related]  

  • 10. Phencyclidine-induced ipsilateral rotation in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra.
    Fessler RG; Sturgeon RD; Meltzer HY
    Life Sci; 1979 Apr; 24(14):1281-8. PubMed ID: 572902
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors.
    Cools AR; van Rossum JM
    Life Sci; 1980 Oct; 27(14):1237-53. PubMed ID: 6255271
    [No Abstract]   [Full Text] [Related]  

  • 12. Behavioral effects of direct- and indirect-acting dopaminergic agonists.
    Moore KE
    Adv Biochem Psychopharmacol; 1974; 12(0):403-14. PubMed ID: 4371765
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in dopamine agonist and antagonist activity following temporary inactivation of the neostraitum.
    Costall B; Naylor RJ; Pettit JC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(2):103-26. PubMed ID: 4281065
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of amantadine and L-dopa on apomorphine- and d-amphetamine-induced stereotyped behaviour in rats.
    Cox B; Tha SJ
    Eur J Pharmacol; 1973 Oct; 24(1):96-100. PubMed ID: 4796449
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of circling models for the detection of antiparkinson activity.
    Costall B; Naylor RJ
    Psychopharmacologia; 1975; 41(1):57-64. PubMed ID: 1091939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Fed Proc; 1978 Jun; 37(8):2181-91. PubMed ID: 350633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 18. Catecholamines, drugs, and behavior: mutual interactions.
    Seiden LS; Campbell AB
    Adv Biochem Psychopharmacol; 1974; 12(0):325-38. PubMed ID: 4418348
    [No Abstract]   [Full Text] [Related]  

  • 19. [Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].
    Pavón N; Vidal L; Alvarez P; Blanco L; Torres A; Rodríguez A; Macías R
    Rev Neurol; 1998 Jun; 26(154):915-8. PubMed ID: 9658459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the interaction between neuroleptics and antiparkinson drugs.
    Julou L
    Mod Probl Pharmacopsychiatry; 1970; 5():50-4. PubMed ID: 5527168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.